These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21030484)

  • 1. Functional selectivity and biased receptor signaling.
    Kenakin T
    J Pharmacol Exp Ther; 2011 Feb; 336(2):296-302. PubMed ID: 21030484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.
    Reiter E; Ahn S; Shukla AK; Lefkowitz RJ
    Annu Rev Pharmacol Toxicol; 2012; 52():179-97. PubMed ID: 21942629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying biased β-arrestin signaling.
    Kenakin T
    Handb Exp Pharmacol; 2014; 219():57-83. PubMed ID: 24292824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands.
    Leduc M; Breton B; Galés C; Le Gouill C; Bouvier M; Chemtob S; Heveker N
    J Pharmacol Exp Ther; 2009 Oct; 331(1):297-307. PubMed ID: 19584306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of conformational ensembles of seven transmembrane receptors in functional selectivity.
    Vaidehi N; Kenakin T
    Curr Opin Pharmacol; 2010 Dec; 10(6):775-81. PubMed ID: 20933468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
    Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
    Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining efficacy: exploiting functional selectivity for drug discovery.
    Gesty-Palmer D; Luttrell LM
    Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Technology Landscape of 7TMR Drug Signaling Profiling.
    Mancini A; Frauli M; Breton B
    Curr Top Med Chem; 2015; 15(24):2528-42. PubMed ID: 26126903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-arrestin-biased ligands at seven-transmembrane receptors.
    Violin JD; Lefkowitz RJ
    Trends Pharmacol Sci; 2007 Aug; 28(8):416-22. PubMed ID: 17644195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biased agonism: An emerging paradigm in GPCR drug discovery.
    Rankovic Z; Brust TF; Bohn LM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):241-250. PubMed ID: 26707396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
    Kenakin T
    Trends Pharmacol Sci; 2007 Aug; 28(8):407-15. PubMed ID: 17629960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of receptor tyrosine kinase signaling by GRKs and beta-arrestins.
    Hupfeld CJ; Olefsky JM
    Annu Rev Physiol; 2007; 69():561-77. PubMed ID: 17002595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G Protein-coupled Receptor Biased Agonism.
    Hodavance SY; Gareri C; Torok RD; Rockman HA
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):193-202. PubMed ID: 26751266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
    Luttrell LM
    Mol Endocrinol; 2014 Mar; 28(3):281-94. PubMed ID: 24433041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seven-transmembrane receptor signaling through beta-arrestin.
    Shenoy SK; Lefkowitz RJ
    Sci STKE; 2005 Nov; 2005(308):cm10. PubMed ID: 16267056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy.
    van der Westhuizen ET; Breton B; Christopoulos A; Bouvier M
    Mol Pharmacol; 2014 Mar; 85(3):492-509. PubMed ID: 24366668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data.
    Stott LA; Hall DA; Holliday ND
    Biochem Pharmacol; 2016 Feb; 101():1-12. PubMed ID: 26478533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pluridimensional View of Biased Agonism.
    Costa-Neto CM; Parreiras-E-Silva LT; Bouvier M
    Mol Pharmacol; 2016 Nov; 90(5):587-595. PubMed ID: 27638872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy.
    Galandrin S; Bouvier M
    Mol Pharmacol; 2006 Nov; 70(5):1575-84. PubMed ID: 16901982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.